Welcome to our dedicated page for Clearside Biomed news (Ticker: CLSD), a resource for investors and traders seeking the latest updates and insights on Clearside Biomed stock.
Clearside Biomedical develops ophthalmic drug-delivery technology for therapies administered to the back of the eye through the suprachoroidal space. News about CLSD centers on the SCS Microinjector platform, the CLS-AX axitinib injectable suspension program for retinal diseases, XIPERE approvals and partner use of the company's suprachoroidal injection technology.
Company updates also cover licensing collaborations, medical-meeting presentations, financial results, Nasdaq listing matters, strategic-alternative reviews and the company's voluntary Chapter 11 restructuring process. These items frame Clearside as a biopharmaceutical issuer built around suprachoroidal delivery, ophthalmology development programs and royalty-related platform assets.
Clearside Biomedical, Inc. (NASDAQ:CLSD) announced the transition of Chief Medical Officer Thomas A. Ciulla, M.D., M.B.A., to Chief Medical Advisor-Retina, effective February 17, 2023. Dr. Ciulla will continue to provide expertise as chair of the Scientific Advisory Board and support the ODYSSEY Phase 2b clinical trial. CEO George Lasezkay highlighted Dr. Ciulla's contributions to the company’s success, particularly in advancing their suprachoroidal delivery platform. The clinical team, led by Chief Clinical Officer Dr. Susan Coultas, is prepared to initiate the ODYSSEY trial, showcasing Clearside's commitment to innovative eye therapies.
Clearside Biomedical, Inc. (Nasdaq: CLSD) announced positive outcomes from the Extension Study of its OASIS Phase 1/2a clinical trial for CLS-AX, a treatment for wet AMD. Key findings show that 67% of study participants went at least six months without additional treatments, experiencing a 77-85% reduction in treatment burden. CLS-AX demonstrated a favorable safety profile with no serious adverse events reported. The upcoming ODYSSEY Phase 2b trial is expected to commence in Q1 2023, aiming to further evaluate CLS-AX's efficacy compared to existing therapies. As of December 31, 2022, Clearside’s cash and cash equivalents stood at approximately $48.3 million.
Clearside Biomedical (NASDAQ:CLSD) has announced its participation in several key conferences this November and December 2022. The events include:
- BTIG Ophthalmology Day on November 29 at 10:30 a.m. ET
- Piper Sandler 34th Annual Healthcare Conference on December 1 at 9:50 a.m. ET
- Ophthalmology Innovation Summit on December 3
- Cantor MedTech Conference on December 8 at 2:45 p.m. ET
Webcasts will be available on the Clearside website under the Investors section, showcasing the company's innovative SCS Microinjector platform for targeted eye therapy delivery.
Clearside Biomedical, Inc. (NASDAQ:CLSD) will participate in a Fireside Chat at the Stifel 2022 Healthcare Conference on November 16, 2022, from 8:35 - 9:05 a.m. Eastern Time. The company's President and CEO, George Lasezkay, and Chief Medical Officer, Thomas A. Ciulla, will discuss Clearside's innovative SCS injection platform that targets therapies to the back of the eye. This platform aims to improve vision preservation and enhance treatment delivery for sight-threatening diseases. Live and archived webcasts will be available on their website.
Clearside Biomedical (NASDAQ:CLSD) announced favorable safety results and efficacy data from its CLS-AX OASIS Phase 1/2a trial in patients with wet AMD. The company is advancing to a larger Phase 2 trial, backed by new funding of up to $65 million from a Royalty Interest Purchase Agreement with HealthCare Royalty Partners. Despite a decline in third-quarter 2022 revenue to $0.3 million from $3.1 million in 2021, R&D expenses decreased to $4.6 million. The net loss for Q3 2022 was $7.8 million, compared to a loss of $4.9 million the previous year. Cash reserves of $53.4 million are projected to extend into 2024.
Clearside Biomedical (Nasdaq:CLSD) reported positive outcomes from its OASIS Phase 1/2a clinical trial for CLS-AX, an injectable suspension aimed at treating neovascular age-related macular degeneration (wet AMD). The study achieved its primary safety endpoint, demonstrating that all doses were well-tolerated with no serious adverse events. Results showed significant durability, with an 88% injection-free rate in Cohorts 3 and 4 at Month 5. The company plans to initiate a Phase 2 trial in Q1 2023 and expects to release final 6-month data from the Extension Study soon.
Clearside Biomedical (NASDAQ:CLSD) will host a conference call on November 9, 2022, at 8:30 a.m. ET to discuss results from its OASIS Phase 1/2a clinical trial of CLS-AX for treating wet AMD patients. The company will also release its financial results for Q3 2022 on the same day. The conference will include key opinion leader Arshad Khanani, M.D., and both live and archived webcasts will be available for investors. Clearside specializes in innovative therapy delivery to the eye through its proprietary SCS Microinjector.
Clearside Biomedical, Inc. (NASDAQ:CLSD) will report its third quarter 2022 financial results on November 9, 2022, before market open. Management will host a conference call at 8:30 a.m. ET to discuss results and provide corporate updates. The call can be accessed at (888) 506-0062 (domestic) or (973) 528-0011 (international) with conference code: 111701. Clearside specializes in innovative therapy delivery to the eye, utilizing its proprietary SCS Microinjector.
Clearside Biomedical (CLSD) has presented promising clinical data regarding its SCS Microinjector, showcased at the American Academy of Ophthalmology 2022 meeting. The data indicate a favorable safety profile and efficacy across various ophthalmic treatments delivered through the suprachoroidal space (SCS). Notably, trials involving gene therapy and small molecules are progressing, with four therapies and six clinical trials currently underway. The interim results from partnered programs demonstrated statistically significant tumor control rates and visual acuity preservation, reinforcing Clearside's leadership in SCS delivery technology.
Clearside Biomedical (NASDAQ: CLSD) announces that clinical trial data for the CLS-AX program related to wet AMD will be reported in November 2022. Dr. Thomas A. Ciulla will present a corporate overview at the Eyecelerator conference on September 29, 2022, during the American Academy of Ophthalmology's Annual Meeting. The OASIS Phase 1/2a trial aims to evaluate the benefits of combining pan-VEGF inhibition with targeted delivery methods using Clearside’s proprietary SCS Microinjector. This highlights the potential advancements in treating sight-threatening eye diseases.